Combining radiotherapy with ripretinib for advanced GIST treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective study aims to evaluate the effectiveness and safety of combining radiotherapy with ripretinib in patients with unresectable advanced gastrointestinal stromal tumors (GIST). The research focuses on whether this combination can prolong the time to disease progression, as ripretinib is currently the standard fourth-line treatment but has limited efficacy. The study utilizes advanced radiotherapy techniques to optimize treatment delivery, potentially improving patient outcomes. By exploring this novel approach, the study seeks to enhance the chances of surgery and improve the quality of life for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntary participation and signed informed consent;
* age: 18 to 75 years, Male or female
* Patients with histologically confirmed GIST and Imaging evaluated as unresectable recurrent and metastatic disease or locally advanced.
* ECOG Performance Score: 0-2
* Subjects who have progressed or documented intolerance after previous first-line, second-line, and third-line treatments.
* At least one measurable lesion in the abdominal or pelvic cavity that has progressed after frontline treatment
* Adequate organ function and bone marrow reserve

Exclusion Criteria:

* estimated life-expectancy less than 3 months.
* Patients who have received previous radiotherapy to the proposed radiotherapy site, or the tumor has significant mobility, poor tolerance of radiotherapy in adjacent organs, and who are considered unsuitable for radiotherapy after MDT discussion
* Any other clinically significant comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
* If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period

Where it's running

• The First Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Principal investigator: Jun Zhang — First Affiliated Hospital of Chongqing Medical University
• Study coordinator: Jun Zhang, MD
• Email: zjun2323@sina.cn
• Phone: +86 136 1766 6067

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DCC-2618 in GIST after at least 3 prior treatments

  This trial tests whether DCC-2618 is safe in people with advanced GIST who have already tried at least three other treatments.

  Recruiting at 2 sites Phase 1 Ono Pharmaceutical Co., Ltd. · Kashiwa, Chiba and 1 other locations · NCT07618377

• Imatinib plus fampridine before surgery for KIT exon 11 gastrointestinal stromal tumor

  This trial tests whether adding fampridine to standard imatinib before surgery is safe and helps shrink KIT exon 11 mutant GIST tumors in adults.

  Recruiting Phase 1 University of California, San Diego · La Jolla, California · NCT07171203

• Testing a new drug for advanced solid tumors that express c-Kit

  This study is testing a new drug for people with advanced solid tumors that have a specific marker called c-Kit to see if it is safe and how well it works.

  Recruiting at 4 sites Phase 1 Novelty Nobility, Inc. · Ann Arbor, Michigan and 4 other locations · NCT06805825

• Understanding genetic causes of neuroendocrine tumors in Mexican patients

  This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.

  Recruiting at 3 sites Universidad Nacional Autonoma de Mexico · Mexico City, Mexico City and 2 other locations · NCT06523582

• Oral Liporaxel (paclitaxel) treatment for gastrointestinal stromal tumors

  This study will test whether taking oral Liporaxel (a form of paclitaxel) can help people with advanced GIST who stopped responding to imatinib, sunitinib, and regorafenib and whose tumors have low P‑glycoprotein levels.

  Recruiting Phase 2 Asan Medical Center · Seoul, Songpagu · NCT06326346

• Safety of laparoscopic surgery for large gastric tumors

  This study is testing whether laparoscopic surgery is safe for people with larger gastric tumors compared to those with smaller ones.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT05938309

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.